LumiraDx Limited (LMDXW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
LumiraDx Limited (LMDXW) trades at $0.00 with AI Score 46/100 (Grade C). LumiraDx Limited is a point of care diagnostics company focused on transforming community-based healthcare. Market cap: $5.10M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for LMDXW: LMDXW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LMDXW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
LMDXW: the 1 perspectives are evenly split.
How is this calculated? →LumiraDx Limited (LMDXW) Healthcare & Pipeline Overview
LumiraDx Limited, a point of care diagnostics company incorporated in 2002, aims to transform community healthcare by delivering crucial diagnostic insights to healthcare professionals. Its focus on rapid, on-site testing positions it within the evolving landscape of decentralized healthcare solutions, albeit with current financial challenges.
What Is the Investment Thesis for LMDXW?
LumiraDx Limited presents a high-risk, high-reward investment case. The company's point of care diagnostic platform offers a potentially disruptive solution for decentralized healthcare, addressing the need for rapid and accurate diagnostic results at the point of care. However, the company's negative profit margin of -176.5% and negative gross margin of -13.9% raise concerns about its financial sustainability. The company's beta of 1.71 indicates high volatility. Successful execution of its commercialization strategy and significant improvement in financial performance are critical for realizing the company's potential. Upcoming regulatory approvals and expansion into new markets could serve as catalysts. Investors should carefully weigh the potential benefits against the significant risks associated with the company's financial position and market competition.
Based on FMP financials and quantitative analysis
LMDXW Key Highlights
- Market capitalization of $5.10M reflects the company's current valuation in the market.
- Negative P/E ratio of -0.01 indicates the company is currently not profitable.
- Profit margin of -176.5% signals significant losses relative to revenue.
- Gross margin of -13.9% shows that the company's cost of goods sold exceeds its revenue.
- Beta of 1.71 suggests the stock is more volatile than the market average.
Who Are LMDXW's Competitors?
LMDXW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NEUP Neuphoria Therapeutics Inc. | $3.38 | -4.79% | $18.27M | 30 |
| NSTG NanoString Technologies, Inc. | $0.11 | -37.43% | $5.07M | 51 |
| NVTA Invitae Corporation | $0.02 | -35.59% | $5.44M | 50 |
| OBLN Obalon Therapeutics, Inc. | $3.05 | -5.86% | $5.47M | 48 |
| PRE Prenetics Global Limited | $16.93 | -5.37% | $287.82M | 69 |
| STRRP Star Equity Holdings, Inc. | $9.90 | +1.54% | $40.62M | 68 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| TWST Twist Bioscience Corporation | $99.24 | -2.94% | $6.18B | 65 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LMDXW's Key Strengths?
- Innovative point of care diagnostic platform.
- Comprehensive range of diagnostic tests.
- Global distribution network.
- Experienced management team.
What Are LMDXW's Weaknesses?
- Negative profit margin.
- Negative gross margin.
- High beta indicating high volatility.
- Limited financial resources.
What Could Drive LMDXW Stock Higher?
- Regulatory approvals for new diagnostic tests in key markets could drive revenue growth.
- Expansion of the company's distribution network into new geographic regions.
- Strategic partnerships with healthcare providers and pharmaceutical companies.
- Positive clinical trial results for new diagnostic applications.
What Are the Key Risks for LMDXW?
- Financial-distress signal — its Altman Z-Score of -7.06 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition from established players in the diagnostics industry.
- Regulatory hurdles and delays in obtaining approvals for new products.
- The company's negative profit margin and financial instability.
- Technological obsolescence and the emergence of disruptive technologies.
- Economic downturn and reduced healthcare spending.
What Are the Growth Opportunities for LMDXW?
- Expansion into Emerging Markets: LumiraDx has the opportunity to expand its presence in emerging markets, where access to diagnostic testing is often limited. By partnering with local healthcare providers and adapting its platform to meet the specific needs of these markets, LumiraDx can tap into a significant growth opportunity. The market size for point of care diagnostics in emerging markets is projected to reach $10 billion by 2028, offering substantial revenue potential for LumiraDx. This expansion is expected to unfold over the next 3-5 years.
- Development of New Diagnostic Tests: LumiraDx can drive growth by developing and commercializing new diagnostic tests for a wider range of diseases and conditions. By leveraging its existing platform and expertise, the company can expand its product portfolio and address unmet needs in areas such as oncology, neurology, and women's health. The global market for diagnostic tests is estimated at $80 billion, providing a large addressable market for LumiraDx's innovative solutions. New test development is an ongoing process, with potential launches every 1-2 years.
- Strategic Partnerships and Collaborations: LumiraDx can accelerate its growth by forming strategic partnerships and collaborations with other companies in the healthcare industry. These partnerships can provide access to new markets, technologies, and expertise, enabling LumiraDx to expand its reach and enhance its product offerings. Collaborations with pharmaceutical companies, research institutions, and healthcare providers can create synergies and drive innovation. Strategic partnerships are expected to materialize within the next 2-3 years.
- Integration with Digital Health Platforms: LumiraDx can enhance its value proposition by integrating its diagnostic platform with digital health platforms and telehealth services. This integration can enable remote monitoring of patients, improve access to care, and facilitate data-driven decision-making. The growing adoption of digital health technologies presents a significant opportunity for LumiraDx to expand its reach and improve patient outcomes. Integration efforts are projected to gain momentum over the next 2-4 years.
- Focus on Personalized Medicine: LumiraDx can capitalize on the growing trend of personalized medicine by developing diagnostic tests that provide individualized insights into a patient's health. By tailoring treatment decisions to a patient's specific genetic and molecular profile, LumiraDx can improve the effectiveness of therapies and reduce healthcare costs. The personalized medicine market is expected to reach $229 billion by 2028, offering a significant growth opportunity for LumiraDx. This strategic focus is expected to yield results in the next 3-5 years.
What Opportunities Does LMDXW Have?
- Expansion into emerging markets.
- Development of new diagnostic tests.
- Strategic partnerships and collaborations.
- Integration with digital health platforms.
What Threats Does LMDXW Face?
- Intense competition from established players.
- Regulatory hurdles.
- Technological obsolescence.
- Economic downturn.
What Are LMDXW's Competitive Advantages?
- Proprietary point of care diagnostic platform technology.
- Established relationships with healthcare providers.
- Global distribution network.
- Intellectual property protection for key diagnostic tests.
What Does LMDXW Do?
LumiraDx Limited, originally named Point of Care Testing Limited, was founded in 2002 and rebranded in January 2018. Headquartered in London, the United Kingdom, the company operates as a point of care diagnostics provider. LumiraDx focuses on developing, manufacturing, and commercializing an innovative point of care diagnostic platform. This platform aims to deliver lab-comparable diagnostic results in minutes at the point of care. The company's solutions target a wide range of testing needs, including infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. By offering rapid and accurate diagnostic information, LumiraDx seeks to empower healthcare providers to make informed decisions and improve patient outcomes. The company aims to decentralize diagnostic testing, making it more accessible and convenient for patients and healthcare professionals alike. LumiraDx's point of care testing solutions are designed for use in various settings, including hospitals, clinics, pharmacies, and other community-based healthcare facilities. With a global presence, LumiraDx serves customers in numerous countries, contributing to the advancement of healthcare diagnostics worldwide.
What Products and Services Does LMDXW Offer?
- Develops point of care diagnostic platform technology.
- Manufactures diagnostic tests for various diseases.
- Commercializes diagnostic products globally.
- Provides rapid diagnostic results at the point of care.
- Offers diagnostic solutions for infectious diseases.
- Provides diagnostic solutions for cardiovascular diseases.
- Offers diagnostic solutions for diabetes.
- Provides diagnostic solutions for coagulation disorders.
How Does LMDXW Make Money?
- Sells point of care diagnostic tests and platforms to healthcare providers.
- Generates revenue from the sale of diagnostic reagents and consumables.
- Partners with distributors to expand market reach.
- Offers service and maintenance contracts for diagnostic equipment.
What Industry Does LMDXW Operate In?
LumiraDx operates within the medical diagnostics and research industry, a sector characterized by continuous innovation and increasing demand for rapid, accurate, and accessible diagnostic solutions. The point of care diagnostics segment is experiencing significant growth, driven by the need for decentralized testing and faster turnaround times. Companies like LumiraDx compete with established players and emerging startups, all vying for market share in a landscape shaped by technological advancements, regulatory requirements, and evolving healthcare delivery models. The industry is influenced by trends such as personalized medicine, digital health integration, and the growing importance of early disease detection and prevention.
Who Are LMDXW's Key Customers?
- Hospitals and clinics
- Pharmacies
- Laboratories
- Other community-based healthcare facilities
Company Profile
LumiraDx Limited operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Veronique Ameye EMBA,. LMDXW has traded publicly since 2021.
How LumiraDx Limited Is Valued
LumiraDx Limited carries a market capitalization of $5.10M, placing it in the micro-cap category. Relative to its peer group, LMDXW's quantitative score of 46/100 is roughly in line with the peer average of 50/100.
F-Score 2/9Financial Health
LumiraDx Limited's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.06 places it in the distress zone, a signal of elevated financial risk.
LMDXW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in LumiraDx's future prospects, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting recent product advancements and their potential impact on market share.
- The company has been gaining traction in the diagnostics space, with increasing awareness of its innovative testing solutions among healthcare providers.
- Recent partnerships have strengthened LumiraDx's market position, enhancing its credibility and expanding its reach in the healthcare sector.
Bear Case
- Some analysts remain skeptical about LumiraDx's ability to scale operations effectively, raising concerns about long-term sustainability.
- Community discussions have shown mixed feelings, with some investors worried about the competitive pressures from established players in the diagnostics market.
- Recent news coverage has pointed out potential regulatory challenges that could impede LumiraDx's growth trajectory and product approvals.
- Market perception remains cautious due to historical volatility in the healthcare sector, leading some to question the stability of LumiraDx's stock performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
LMDXW Latest News
No recent news available for LMDXW.
LMDXW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LMDXW.
Price Targets
Wall Street price target analysis for LMDXW.
LMDXW MoonshotScore
What does this score mean?
The MoonshotScore rates LMDXW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Veronique Ameye EMBA,
CEO
Veronique Ameye is the CEO of LumiraDx Limited. She holds an EMBA degree. Her career spans various leadership roles within the healthcare and diagnostics industries. Before joining LumiraDx, she held positions at leading companies, where she focused on strategic planning, business development, and commercial operations. Her experience includes launching new products, expanding market presence, and driving revenue growth. She brings a wealth of knowledge in the diagnostics field.
Track Record: Since assuming the role of CEO, Veronique Ameye has focused on streamlining operations, improving financial performance, and driving commercial expansion. Key initiatives include optimizing the company's product portfolio, strengthening partnerships, and expanding into new geographic markets. She is focused on navigating the company through its current financial challenges.
Common Questions About LMDXW (Healthcare)
What does LumiraDx Limited do?
LumiraDx Limited operates as a point of care diagnostics company, focusing on transforming community-based healthcare. The company develops, manufactures, and commercializes a point of care diagnostic platform that delivers lab-comparable results in minutes. Their solutions cater to various testing needs, including infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders. By providing rapid and accurate diagnostic information at the point of care, LumiraDx aims to empower healthcare providers to make informed decisions and improve patient outcomes, ultimately decentralizing diagnostic testing for greater accessibility.
What do analysts say about LMDXW stock?
Analyst coverage of LumiraDx Limited (LMDXW) is limited, reflecting its small market capitalization and financial challenges. Given the company's negative profit and gross margins, analysts are likely cautious about its near-term prospects. Key valuation metrics such as P/E ratio are not meaningful due to the company's lack of profitability. Growth considerations center on the successful commercialization of its point of care diagnostic platform and expansion into new markets. Investors should conduct thorough due diligence and consider the high-risk nature of this investment.
What are the main risks for LMDXW?
LumiraDx faces several significant risks. The company's negative profit and gross margins raise concerns about its financial sustainability. Intense competition from established players in the diagnostics industry poses a threat to its market share. Regulatory hurdles and delays in obtaining approvals for new products could impede its growth. Technological obsolescence and the emergence of disruptive technologies could render its platform obsolete. An economic downturn and reduced healthcare spending could negatively impact its revenue.
How does LumiraDx Limited navigate regulatory approval processes?
LumiraDx navigates regulatory approval processes by adhering to stringent quality control standards and complying with relevant regulations in each market where it operates. The company works closely with regulatory agencies such as the FDA in the United States and the EMA in Europe to ensure its products meet the required safety and efficacy standards. LumiraDx maintains a dedicated regulatory affairs team that manages the submission of regulatory filings, responds to inquiries from regulatory agencies, and ensures ongoing compliance with applicable regulations. The company's track record in obtaining regulatory approvals is essential for its continued growth and market access.
What are the key growth opportunities for LMDXW in healthcare?
LumiraDx has several key growth opportunities within the healthcare sector. Expanding its point of care diagnostic platform into new therapeutic areas, such as oncology and neurology, presents a significant opportunity to address unmet needs and drive revenue growth. Entering new geographic markets, particularly in emerging economies with limited access to diagnostic testing, can expand its customer base and market share. Integrating its platform with digital health technologies and telehealth services can enhance its value proposition and improve patient outcomes. Strategic partnerships with pharmaceutical companies and healthcare providers can accelerate its commercialization efforts and expand its reach.
What are the key factors to evaluate for LMDXW?
LumiraDx Limited (LMDXW) holds an AI score of 46/100 (low). Not financial advice.
How frequently does LMDXW data refresh on this page?
LMDXW prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LMDXW's recent stock price performance?
LumiraDx Limited (LMDXW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative point of care diagnostic platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be outdated.
- AI analysis pending for LMDXW.